The use of the regulatory polypeptide Selank and combined phototherapy to enhance the efficiency of treatment in patients with atopic dermatitis

In view of the insufficient efficiency of the currently known procedures to treat patients with atopic dermatitis (AD), there is a need to search for new approaches to solving this problem. Objective: to elaborate a therapeutic approach to treating patients with AD on the basis of combination use along with basic agents, as well as a drug from the group of regulatory peptides (such as Selank) and combined phototherapy (CPT). Subjects and methods. A group of 124 patients (mean age, 23.70±6.06 years) underwent a comparative evaluation of the efficiency of basic drug therapy (BDT) for AD, by additionally using the regulatory polypeptide Selank and CPT (narrowband medium-wave and broadband long-wave radiation (UVB-311 nm/ UVA-320-400 nm)), as well as combinations thereof. Results. The combined use of BDT, Selanka, and CPT revealed the potentiation of the clinical effects of the therapeutic procedures used. At 1-year follow-up, the relative risk reduction in disease recurrence was 36% in the Selank + BDT group, 42% in the CPT + BDT group, and 78% in the Selank + CPT + BDT group, as compared to the BDT group. Conclusion. The developed treatment option provides the most effective reduction (78.8%) in the severity of cutaneous manifestations of AD, as shown by the SCORAD index, a 64.7% improvement in quality of life, and a 78% relative risk reduction in disease recurrence, as compared to BDT results.

dermatology, therapy, atopic dermatitis, Selank, combined phototherapy